Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25188850 | 0.98 | CES1 (0.46) | CES1ANPEPKDM4ECYP1A2HPGD | |
| SCHEMBL30783256 | 0.91 | HPRT1 (0.47) | CES1ANPEPKDM4ECYP1A2HPGD | |
| SCHEMBL16337407 | 0.91 | HPRT1 (0.47) | CES1ANPEPKDM4ECYP1A2HPGD | |
| SCHEMBL29906430 | 0.76 | GAA (0.40) | CES1ANPEPKDM4ECYP1A2HPGD | |
| SCHEMBL29699581 | 0.73 | GSK3A (0.31) | GSK3AGSK3B | |
| SCHEMBL29399101 | 0.71 | HSD17B10 (0.44) | CES1KDM4ECYP1A2HPGDCYP2C19 | |
| SCHEMBL2290546 | 0.71 | HSD17B10 (0.44) | CES1KDM4ECYP1A2HPGDCYP2C19 | |
| SCHEMBL1505694 | 0.70 | ANPEP (0.41) | CES1ANPEPHSD17B10ALDH1A1PAX8 | |
| SCHEMBL10980592 | 0.70 | ERN1 (0.39) | KDM4EHPGDHSD17B10GLAALDH1A1 | |
| SCHEMBL9350114 | 0.70 | KDM4E (0.39) | ANPEPKDM4ECYP1A2HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110769832-B | Use of 20-hydroxyecdysone and derivatives thereof in myopathy treatment | 比奥菲蒂斯公司 | 2023-08-01 | — | — | CN | claimed |
| CN-115776892-A | Botanical ecdysone and derivatives thereof for use in the treatment of respiratory dysfunction caused by viral infection | 比奥菲蒂斯公司 | 2023-03-10 | — | — | CN | claimed |
| EP-4125922-A1 | PHYTOECDYSONES AND DERIVATIVES THEREOF FOR USE IN TREATING DISORDERED RESPIRATORY FUNCTION ON VIRAL INFECTION | Biophytis (FR) | 2023-02-08 | — | — | EP | claimed |
| CN-110198949-B | Process for the preparation of 9 beta, 10 alpha-progesterone (retroprogesterone) | 工业化学有限公司 | 2022-05-10 | — | — | CN | claimed |
| EP-3937948-A1 | PHYTOECDYSONES AND THE DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | Biophytis (FR) | 2022-01-19 | — | — | EP | claimed |
| EP-3937949-A1 | PHYTOECDYSONES AND THE DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF IMPAIRED LUNG FUNCTION | Biophytis (FR) | 2022-01-19 | — | — | EP | claimed |
| EP-3758709-A1 | PHYTOECDYSONES FOR USE IN THE PREVENTION OF MUSCLE STRENGTH LOSS DURING IMMOBILISATION | Biophytis (FR) | 2021-01-06 | — | — | EP | claimed |
| WO-2020187678-A1 | PHYTOECDYSONES AND THE DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | BIOPHYTIS (FR) | 2020-09-24 | — | — | WO | claimed |
| WO-2020187679-A1 | PHYTOECDYSONES AND THE DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF IMPAIRED LUNG FUNCTION | BIOPHYTIS (FR) | 2020-09-24 | — | — | WO | claimed |
| EP-3615035-A1 | USE OF 20-HYDROXYECDYSONE AND THE DERIVATIVES THEREOF IN THE TREATMENT OF MYOPATHIES | Biophytis (FR) | 2020-03-04 | — | — | EP | claimed |
| EP-2527345-B1 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS INC (US) | 2015-12-16 | — | — | EP | claimed |
| EP-2688570-B1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS | ENDECE LLC (US) | 2015-11-18 | — | — | EP | claimed |
| WO-2014089904-A1 | TRIAZINONE COMPOUNDS | ABBVIE INC. (US) | 2014-06-19 | — | — | WO | claimed |
| EP-2507253-A2 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE | Endece, LLC (US) | 2012-10-10 | — | — | EP | claimed |
| WO-2011066542-A2 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE | ENDECE INC. (US) | 2011-06-03 | — | — | WO | claimed |
| US-20260083755-A1 | TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION | Neurocrine UK Limited (GB) | 2026-03-26 | — | — | US | disclosed |
| CN-120152967-A | Bifunctional compounds containing 2, 5-substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-1399406-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS I | KAROBIO AB (SE) | 2005-08-10 | — | — | EP | disclosed |
| WO-2002053522-A2 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS I | KARO BIO AB (SE) | 2002-07-11 | — | — | WO | disclosed |
| EP-0090516-B1 | SUBSTITUTED HEXAHYDROPYRROLO(1,2-A)-QUINOLINE, HEXAHYDRO-1H-PYRIDO(1,2-A)-QUINOLINE, HEXAHYDROBENZO(3)INDENE AND OCTAHYDROPHENANTHRENE CNS AGENTS | PFIZER INC. (US) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083755-A1 | TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION | SHBG, TES, CYP17A1 | CES1 418/4885ANPEP 2469/4885KDM4E 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.